Get the Stockscreener App
1.74
0.58%
0.01
After Hours:
1.78
0.04
+2.30%
Gain Therapeutics Inc stock is traded at $1.74, with a volume of 258.49K.
It is up +0.58% in the last 24 hours and down -34.34% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$1.73
Open:
$1.79
24h Volume:
258.49K
Relative Volume:
0.68
Market Cap:
$47.48M
Revenue:
$210.70K
Net Income/Loss:
$-22.22M
P/E Ratio:
-0.956
EPS:
-1.82
Net Cash Flow:
$-17.13M
1W Performance:
+4.82%
1M Performance:
-34.34%
6M Performance:
-28.10%
1Y Performance:
-22.32%
1-Day Range:
$1.71
$1.8616
1-Week Range:
$1.56
$1.895
52-Week Range:
$0.89
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.74 | 47.48M | 210.70K | -22.22M | -17.13M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
HC Wainwright Reaffirms “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Stock market today: Poseida Therapeutics +224.30%, Primega Group Holdings +98.77% among the top gainers in early trading - Business Upturn
Gain Therapeutics shares hold Buy rating; H.C. Wainwright optimistic on GT-02287 clinical data - Investing.com Canada
FY2024 Earnings Forecast for GANX Issued By Chardan Capital - Defense World
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Nasdaq
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
Stock market news: Renewable Japan jumps nearly 69% by mid-day, D. Western Therapeutics and Agile Media Network post strong gains - Business Upturn
Gain Therapeutics Advances Parkinson’s Therapy Development - TipRanks
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 15.1% in October - Defense World
Chesapeake Granite Wash Trust (OTCMKTS:CHKR) Sees Large Increase in Short Interest - Defense World
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Tapestry (NYSE:TPR) Price Target Raised to $66.00 - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Gain Therapeutics Inc (GANX) Quarterly 10-Q Report - Quartz
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update - The Manila Times
Gain Therapeutics' Parkinson's Drug Shows 53% Activity Boost in Phase 1 Trial | GANX Stock News - StockTitan
The Future Of Inflammation: The Inflammasome And Beyond - Citeline News & Insights
Insiders of Tectonic Therapeutic, Inc. (NASDAQ:TECX) were rewarded after last week’s 10% gain - Simply Wall St
Endeavour Silver Corp (EXK) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
Canada Market top gains:Q2 Metals Corp rises 17.00% while Valeura Energy climbs 15.55% at midday - Business Upturn
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Yahoo Finance
Hoping for a weight-loss pill? It could get closer to reality next week. - MarketWatch
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? - Yahoo Finance
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6% - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Nuclear stocks gain on AI optimism: Oklo, NuScale, Centrus - Yahoo Finance
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - The Manila Times
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance
Gain Therapeutics Regains Nasdaq Compliance - Investing.com
Gain Therapeutics Regains Nasdaq Compliance By Investing.com - Investing.com UK
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - MSN
32 NMEs gain US FDA clearance through Q3, approvals up over 2023 - BioWorld Online
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
How should investors view Janux Therapeutics Inc (JANX)? - US Post News
What was Gain Therapeutics Inc (GANX)’s performance in the last session? - US Post News
Gain Therapeutics Inc [GANX] Investment Guide: What You Need to Know - Knox Daily
GANX Stock: A Voyage Through Gain Therapeutics Inc’s Finances - The InvestChronicle
Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):